Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 29, 2011 Brian Orelli	What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies.
The Motley Fool October 6, 2011 Brian Orelli	Data Published; Back to Waiting Phase 2 data for Aeterna Zentaris and Keryx's perifosine was published, but it's the phase 3 that's important.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool July 29, 2011 Brian Orelli	2 Biotechs, 1 Promising Cancer Drug Perifosine on the home stretch.
The Motley Fool December 29, 2006 Brian Lawler	Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide.
The Motley Fool October 22, 2010 Luke Timmerman	Aastrom Maps Out Pivotal Trial Strategy With Adult Stem Cell Therapy Aastrom needs a good strategy for working with U.S. drug regulators.
The Motley Fool September 27, 2011 Brian Orelli	Promising Results, But It's Still Early Aeterna Zentaris' investors got a bit of good news yesterday while they wait for phase 3 data for the company's colorectal cancer drug perifosine.
The Motley Fool September 20, 2007 Brian Orelli	Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note.
The Motley Fool November 28, 2011 Brian Orelli	Breaking Down a Biotech Press Release Aeterna Zentaris: FDA Grants IND to Investigator at Baylor College of Medicine for Phase 2A Trial with AEZS-130 in Cancer Cachexia. That sure is a mouthful. Let's see if we can break it down.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
The Motley Fool December 14, 2006 Brian Lawler	Vertex: Coming Together Nicely If telaprevir continues to show anything like the 80%-90% rate of undetectable hepatitis C virus at end of its trials, Vertex shareholders won't be dealing with too many more down days.
The Motley Fool September 11, 2007 Brian Orelli	A Waiting Game for Aspreva It will be three years before Aspreva Pharmaceuticals and partner Roche evaluate results for a treatment for lupus. If and when the drug is approved, it will have to compete with a whole host of other drugs currently in trials. Investors take note.
The Motley Fool November 20, 2006 Brian Lawler	One-and-a-Half Setbacks for Exelixis Drug development is a long process usually involving many setbacks and failures, even for the most successful drug makers. Investors in this biotech shouldn't worry too much about this one.
The Motley Fool December 31, 2010 Brian Orelli	CEL-SCI Investors Cheer a Bit Too Loudly Finally, a phase 3 trial for cancer therapy Multikine.
The Motley Fool September 13, 2007 Brian Orelli	Alfacell's Awkward Wait Waiting for subjects to die is a somber part of the oncology clinical trial process. Alfacell is doing just that in its final phase three trial with its lead cancer drug candidate. Investors take note.
The Motley Fool November 29, 2004 Charly Travers	Genta Is Worth Nada Latest trial failure leaves the pharmaceutical company with few options. Without Genasense, Genta is essentially a shell of a company with no means of creating value for shareholders.
The Motley Fool October 29, 2007 Brian Lawler	World's Scariest Stock: Dendreon Investing in the biotech sector is scary enough for most investors. Dendreon's scary future should makes this stock an under-performer.
The Motley Fool June 4, 2007 Brian Lawler	Is AtheroGenics Grasping at Straws? The pharmaceutical announces the path forward for its lead drug. Investors, take note.
The Motley Fool March 13, 2007 Brian Lawler	Panacos Springs Ahead Panacos advances its lead drug program.
The Motley Fool December 16, 2009 Brian Orelli	Gilead's Phase 3 Train Wreck Gilead Sciences' darusentan looked so promising.
The Motley Fool October 24, 2006 Brian Lawler	Playing the AtheroGenics Waiting Game The results of phase 3 trials for the company's atherosclerosis drug will determine AtheroGenics' future. Investors, take note.
The Motley Fool October 24, 2011 Brian Orelli	Biotech Blunder Turned 20% Overnight Gain Exelixis gets good data, even if it wasn't exactly what it was expecting.
The Motley Fool March 20, 2007 Brian Lawler	Heart Attack at AtheroGenics Shares of AtheroGenics drop after negative phase 3 trial results.
The Motley Fool May 31, 2011 Brian Orelli	5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals.
The Motley Fool December 31, 2011 Brian Orelli	3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012.
The Motley Fool October 1, 2009 Brian Orelli	Geez, Lighten Up, Mr. Market! Investors dish out undue punishment to Onyx's stock.
The Motley Fool March 16, 2011 Brian Orelli	Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial.
The Motley Fool December 27, 2006 Brian Lawler	Telik Falls Short Shares of another biopharma fall after disappointing clinical trial results.
The Motley Fool December 11, 2008 Brian Orelli	ASH Wrap-Up: Alphabet Soup and Drugs Let's take a look at the data that came out of the American Society of Hematology meeting regarding pharmaceutical companies' medications for blood diseases.
The Motley Fool October 2, 2007 Brian Orelli	Regeneron Sees Positive Phase 2 Data Regeneron Pharmaceuticals and partner Bayer HealthCare see a bright future for their age-related macular degeneration treatment after announcing positive phase 2 data.
The Motley Fool June 18, 2008 Brian Lawler	Elan's and Wyeth's Data: Success or Failure? Elan and partner Wyeth released new mid-stage data for their potential blockbuster bapineuzumab (AAB-001) for Alzheimer's disease, but the results aren't conclusive.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
The Motley Fool September 30, 2010 Brian Orelli	Bristol-Myers' Delayed Steal ZymoGenetics price tag looks more reasonable.
The Motley Fool February 26, 2007 Brian Lawler	Waiting on AtheroGenics The results might be positive for this pharma, but don't bet on it. Investors, take note.
The Motley Fool January 18, 2012 Brian Orelli	2 High-Flying Biotechs Face a New Hurdle The next number-one concern for Aeterna Zentaris' and Keryx's investors should be whether the drug passes its clinical trial.
The Motley Fool June 5, 2007 Brian Lawler	Exelixis Presents The pharmaceutical presents data from 2 of its top drug candidates at ASCO. Investors, take note.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
The Motley Fool September 21, 2007 Brian Orelli	Size Does Matter BioCryst announces failed phase 2 data with an excuse, and plans phase 3 before year-end. Investors, take note.
The Motley Fool July 10, 2006 Brian Lawler	Northfield Frowns on Focus From "20/20" The maker of artificial blood finds yet another critic. But the impending end of the PolyHeme trial probably won't represent the end of criticism of the artificial blood. Only if good clinical trial results are announced later this year will Northfield's critics be silenced.
The Motley Fool October 8, 2010 Brian Orelli	Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size.
The Motley Fool September 29, 2006 Brian Lawler	The Long Road Ahead for ViroPharma Faced with the threat of generic competition, the company focuses its efforts on a new drug. ViroPharma investors should watch intently.
The Motley Fool September 25, 2007 Brian Lawler	Amgen's European Adventures The European Medicines Agency announces that it has reversed its decision on Amgen's cancer drug Vectibix, allowing it on the market for a limited patient population. Investors, take note.
The Motley Fool November 19, 2010 Brian Orelli	Exelixis: Up 32% With Room to Run It was only a phase 2 trial, after all.
The Motley Fool October 5, 2005 Stephen D. Simpson	Lupus Trials Spook Investors Lupus is a high-risk, high-reward indication, and today's disappointing trial results aren't the end of the story for Human Genome Sciences. Aggressive and experienced investors might want to take a look at this one, but this is clearly not a stock for the faint of heart.
The Motley Fool September 27, 2010 Brian Orelli	Better Buy: Ariad Pharmaceuticals or Corcept Therapeutics? A battle of drugless companies looking for their first hit.
The Motley Fool October 7, 2008 Brian Orelli	Results IMPACT Volatility at Dendreon Dendreon almost hits both a 52-week high and a 52-week low on the day it releases results.
The Motley Fool December 11, 2006 Brian Lawler	Acorda Calls for 2 More Trials It'll be awhile before the FDA makes its decision on the pharma's new MS drug and the stock price settles down.
The Motley Fool May 15, 2007 Mike Havrilla	A Tale of Two Trials at YM Bio Encouraging results and ongoing drug trials give YM BioSciences' investors hope.
The Motley Fool December 5, 2006 Brian Lawler	Slight Setback for Onyx Onyx shares fell on disappointing news, but there are other opportunities for the one-drug wonder.